| Status: Under consideration by AWMSG Scrutiny Panel | |
In combination with oxaliplatin, 5-fluorouracil (5-FU) and leucovorin (LV) for the first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas. This medicine was considered by AWMSG Scrutiny Panel on 7th August 2025. It was considered suitable for assessment by LOWMAG
|
|
Medicine details |
|
| Medicine name | pegylated liposomal irinotecan (Onivyde®) |
| Formulation | 4.3 mg/ml concentrate for solution for infusion |
| Reference number | 6200 |
| Indication | As above |
| Company | Servier Laboratories Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | Under consideration |
| Status | Under consideration by AWMSG Scrutiny Panel |
| Scrutiny Panel meeting date | 07/08/2025 |
| NICE guidance | |
| Further information This medicine was considered by AWMSG Scrutiny Panel on 7 August 2025. Pegylated liposomal irinotecan (Onivyde®) is suitable for a full HTA assessment via the Licensed Medicines One Wales Medicines Assessment Group (LOWMAG). A Welsh Patient Access Scheme (WPAS) has already been agreed through the Commercial Arrangement Scheme Wales Group (CASWG). Clinicians highlighted the unmet clinical need for this medicine. This medicine is not routinely available across other UK countries and there is no UK clinical guidance available, it was therefore deemed suitable for full HTA assessment. A full submission has been requested from the company. |
|